Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity
ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world's leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product.
Monrol and FutureChem Announced a Clinical Supply Partnership
ISTANBUL & SEOUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea, a radiopharmaceutical company, for the clinical supply of radioisotope, Lu-177 n.c.a. (Lutetium-177 non-carrier-added), to support FutureChem’s Investigational New Drug IND-enabling...
Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany
ISTANBUL--(BUSINESS WIRE)--Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany.
Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses...
ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced that the first patient has been dosed in the ‘STARLITE 2’ Phase II study of Telix Pharmaceuticals Limited (Telix) investigational renal cancer therapy product, TLX250 (177Lu-DOTA-girentuximab)...
Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium
ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added177Lu (n.c.a.177Lu) cutting-edge production technology LuMagic®.
MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.
WEST CHESTER, Pa. & ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added177Lu (n.c.a.177Lu).
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
MELBOURNE, Australia and ISTANBUL, Turkey, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) and Eczacıbaşı-Monrol Nuclear Products Co. (‘Eczacıbaşı Monrol’) are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Turkey.
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol.
Monrol and ImaginAb Announce Supply, Manufacturing and Distribution Partnership
Inglewood, California and Istanbul, Turkey – June 9, 2022 - ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radioligand therapy (RLT), is delighted to announce that it has reached an agreement, in principle with Turkey-based Radiopharmaceuticals company, Monrol, for the supply of radioisotopes, Zirconium-89 (Zr-89) and Lutetium-177 nca (Lu-177), in diagnostic imaging and radiopharmaceutical therapy, respectively.